ARWR · Arrowhead Pharmaceuticals, Inc. · Proposed Sales
$44.56
-3.22 (-6.74%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q4 2026 earnings call transcript
Market Cap
$6.75B
Shares
141.37M
Volume · Nov 16
853.28K
Avg daily vol (3M)
1.92M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-03-05 | James Hamilton | Officer | 10,000 | 2026-03-05 | Merrill Lynch |
| 2026-01-05 | James Hamilton | Officer | 39,728 | 2026-01-05 | Merrill Lynch |
| 2026-01-05 | Patrick O'Brien | Officer | 49,493 | 2026-01-05 | Merrill Lynch |
| 2026-01-02 | Christopher Anzalone | Officer | 13,187 | 2026-01-02 | Merrill Lynch |
| 2025-12-29 | Christopher Anzalone | Officer | 51,726 | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | Mauro Ferrari | Director | 7,530 | 2025-12-26 | Merrill Lynch |
| 2025-12-22 | Christopher Anzalone | Officer | 12,586 | 2025-12-22 | Merrill Lynch |
| 2025-12-19 | Victoria Vakiener | Director | 10,040 | 2025-12-19 | Merrill Lynch |
| 2025-12-19 | Adeoye Olukotun | Director | 10,000 | 2025-12-19 | Merrill Lynch |
| 2025-12-19 | Christopher Anzalone | Officer | 13,445 | 2025-12-19 | Merrill Lynch |
| 2025-12-19 | William Waddill | Director | 8,367 | 2025-12-19 | Merrill Lynch |
| 2025-12-17 | Christopher Anzalone | Officer | 85,000 | 2025-12-17 | Merrill Lynch |
| 2025-12-16 | Christopher Anzalone | Officer | 54,298 | 2025-12-16 | Merrill Lynch |
| 2025-12-15 | Christopher Anzalone | Officer | 130,000 | 2025-12-15 | Merrill Lynch |
| 2025-12-05 | Michael Perry | Director | 16,250 | 2025-12-05 | Merrill Lynch |
| 2025-11-28 | Mauro Ferrari | Director | 8,750 | 2025-11-28 | Merrill Lynch |
| 2025-10-01 | James Hamilton | Officer | 20,000 | 2025-10-01 | Merrill Lynch |
| 2025-09-12 | Hamilton James C | Officer | 15,000 | 2025-09-12 | Merrill Lynch |
| 2025-09-02 | Hamilton James C | Officer | 15,000 | 2025-09-02 | Merrill Lynch |
| 2025-08-15 | Hamilton James C | Officer | 9,389 | 2025-08-15 | Merrill Lynch |
| 2025-08-13 | Hamilton James C | Officer | 611 | 2025-08-13 | Merrill Lynch |
| 2025-08-13 | Sarepta Therapeutics, Inc. | Shareholder | 9,265,312 | 2025-08-13 | Jefferies LLC |
| 2025-07-10 | Myszkowski Kenneth Allen | Officer | 40,000 | 2025-07-10 | Merrill Lynch |
| 2025-04-11 | Anzalone Christopher Richard | Officer | 50,800 | 2025-04-11 | Merrill Lynch |
| 2025-04-10 | Anzalone Christopher Richard | Officer | 50,000 | 2025-04-10 | Merrill Lynch |
| 2025-04-09 | Anzalone Christopher Richard | Officer | 40,322 | 2025-04-09 | Merrill Lynch |
| 2025-03-13 | Anzalone Christopher Richard | Officer | 51,425 | 2025-03-13 | Merrill Lynch |
| 2025-03-04 | Anzalone Christopher Richard | Officer | 133,333 | 2025-03-04 | Merrill Lynch |
| 2025-03-03 | Anzalone Christopher Richard | Officer | 166,667 | 2025-03-03 | Merrill Lynch |
| 2025-01-23 | OLUKOTUN ADEOYE Y | Director | 959 | 2025-01-23 | Merrill Lynch |
| 2025-01-07 | O'Brien Patrick | Officer | 8,000 | 2025-01-07 | Merrill Lynch |
| 2025-01-07 | Myszkowski Kenneth Allen | Officer | 8,000 | 2025-01-07 | Merrill Lynch |
| 2025-01-07 | Myszkowski Kenneth Allen | Officer | 10,000 | 2025-01-07 | Merrill Lynch |
| 2025-01-06 | Hamilton James C | Officer | 32,729 | 2025-01-06 | Merrill Lynch |
| 2025-01-06 | Myszkowski Kenneth Allen | Officer | 5,817 | 2025-01-06 | Merrill Lynch |
| 2025-01-06 | O'Brien Patrick | Officer | 29,184 | 2025-01-06 | Merrill Lynch |
| 2025-01-06 | Myszkowski Kenneth Allen | Officer | 5,817 | 2025-01-06 | Merrill Lynch |
| 2025-01-06 | Myszkowski Kenneth Allen | Officer | 9,255 | 2025-01-06 | Merrill Lynch |
| 2025-01-06 | Myszkowski Kenneth Allen | Officer | 6,287 | 2025-01-06 | Merrill Lynch |
| 2025-01-02 | Anzalone Christopher Richard | Officer | 11,520 | 2025-01-02 | Merrill Lynch |
| 2024-12-27 | OLUKOTUN ADEOYE Y | Director | 2,850 | 2024-12-27 | Merrill Lynch |
| 2024-12-23 | Anzalone Christopher Richard | Officer | 12,563 | 2024-12-23 | Merrill Lynch |
| 2024-12-18 | Anzalone Christopher Richard | Officer | 26,712 | 2024-12-18 | Merrill Lynch |
| 2024-12-17 | Waddill William D. | Director | 3,747 | 2024-12-17 | Merrill Lynch |
| 2024-12-17 | GIVEN DOUGLAS B | Director | 547 | 2024-12-17 | Merrill Lynch |
| 2024-12-16 | Waddill William D. | Director | 3,748 | 2024-12-16 | Merrill Lynch |
| 2024-12-16 | GIVEN DOUGLAS B | Director | 5,000 | 2024-12-16 | Merrill Lynch |
| 2024-12-16 | Vakiener Victoria | Director | 8,994 | 2024-12-16 | Merrill Lynch |
| 2024-07-02 | Oliver Tracie | Officer | 9,394 | 2024-07-02 | Merrill Lynch |
| 2024-05-02 | Vakiener Victoria | Officer | 1,799 | 2024-05-02 | Merrill Lynch |
Showing 1–50 of 79 filings
Key facts
CIK
879407
CUSIP
04280A100
13F (30d)
365 filings
343 filers
Visit website
Investor relations